Alopecia areata (AA) is a type of non-scarring hair loss. While the exact cause is not fully understood, new insights in disease understanding suggest an autoimmune pathology. The inflammatory pathways associated with AA destroy most of the hair follicle but spare the upper portion, giving rise to the possibility of hair regrowth and new targeted treatments that may improve patient outcomes. Therefore, staying up to date on current and emerging data for AA treatments is necessary to enhance comprehension of AA pathophysiology, assess patients, and inform potential treatment targets.
In the first installment of this three-part virtual Journal Club series, More Than Hair Loss: Understanding the Role the Immune System Plays in Developing Alopecia Areata and Its Treatment Implications, Dr. Emma Guttman-Yassky will present up-to-date information on the pathophysiology and specific immunologic pathways that affect AA.
At the end of this CME/CE activity, participants should be able to outline the pathophysiology of AA.
Supported by an educational grant from Pfizer Inc.
Physicians, PAs, and nurse practitioners specializing in dermatology, allergy/immunology, general practice, and/or pediatrics located outside of the United States
it is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Guttman-Yassky reports the following financial relationships:
Consultant: AbbVie Inc; Almirall; Amgen Inc.; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; ASLAN Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Cara Therapeutics; Celgene Corporation; Connect Biopharma; Eli Lilly and Company; EMD Serono; Evidera; Galderma; Ichnos Sciences Inc.; Incyte; Janssen Biotech, Inc.; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Pandion Therapeutics; Pfizer Inc.; RAPT Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; SATO Pharmaceutical, Co., Ltd; Siolta Therapeutics; Target PharmaSolutions, Inc.; UCB, Inc.; and Ventyx Biosciences, Inc.
Grants (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Pharmaceuticals, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.
Research Support (Paid to Icahn School of Medicine at Mount Sinai): AbbVie Inc; Almirall; Amgen Inc.; AnaptysBio, Inc.; Asana BioSciences, LLC; AstraZeneca; Boehringer Ingelheim; Cara Therapeutics; Celgene Corporation; Eli Lilly and Company; Galderma; Glenmark Pharmaceutical Inc./Ichnos Sciences Inc.; Innovaderm; Janssen Biotech, Inc.; Kao Corporation; Kiniksa Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd; LEO Pharma Inc.; Novan, Inc.; Novartis; Pfizer Inc.; Ralexar Therapeutics, Inc.; Regeneron Pharmaceuticals Inc; and UCB, Inc.
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
This activity is also offered in Podcast and Webcast formats
Call us at 877.CME.PROS (877.263.7767).